Original language | English (US) |
---|---|
Pages (from-to) | E201-E202 |
Journal | Stroke |
Volume | 54 |
Issue number | 5 |
DOIs | |
State | Published - May 1 2023 |
Funding
Dr de Havenon receives research funding from the National Institutes of Health (NIH), consultant fees from Integra and Novo Nordisk, royalty fees from UpToDate, and equity in TitinKM and Certus. Dr Cramer serves as a consultant for Abbvie, Constant Therapeutics, MicroTransponder, Neurolutions, SanBio, Panaxium, NeuExcell, Elevian, Medtronic, Helius, Omniscient, and TRCare. Dr Lindgren reports personal fees from Bayer, NovoNordisk, Astra Zeneca, and BMS Pfizer. Dr Skolarus reports research funding from NIH and American Heart Association, and employment by University of Michigan and Northwestern. The other authors report no conflicts.
Keywords
- albumin
- ethnicity
- hyperglycemia
- ischemic stroke
- odds ratio
ASJC Scopus subject areas
- Clinical Neurology
- Cardiology and Cardiovascular Medicine
- Advanced and Specialized Nursing